FOLH1 and prostate carcinoma: Doxorubicin was loaded onto QDs doped with an aptamer that recognizes the PSMA protein on prostate cancer cells. This delivery system features an on/off switch using QDs’ fluorescence to indicate the release of Dox from the delivery complex